glp 1 gip dual agonist lilly Lilly's Investigational and GLP-1 Receptor Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes Lilly's Investigational Dual GIP and

Encourages balanced appetite & cravings*

One of the largest US health insurers is ending coverage of GLP-1 weight-loss drugs for its employees but will continue covering them for people with type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity

Originally developed for diabetes management, these therapies have demonstrated significant effectiveness in weight management and are reshaping conversations around obesity treatment, chronic disease prevention, and long-term healthcare costs

Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking treatment for Type 2 diabetes mellitus (T2DM) and obesity